National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Behavioral Health (1)
- Children/Adolescents (1)
- Evidence-Based Practice (1)
- Health Insurance (1)
- (-) Human Immunodeficiency Virus (HIV) (4)
- Medicaid (1)
- (-) Medication (4)
- Opioids (1)
- (-) Outcomes (4)
- Patient-Centered Outcomes Research (2)
- Patient Adherence/Compliance (1)
- Substance Abuse (1)
- Treatments (1)
- Young Adults (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedKorthuis PT, Cook RR, Lum PJ
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Opioid Use Disorder (OUD) treatment medications can improve outcomes for human immunodeficiency virus (HIV) and also reduce opioid use. The purpose of the study was to determine if outpatient naltrexone treatment could also reduce opioid use and improve outcomes for HIV. The researchers reported that enrollment was stopped early because of slower than expected recruitment, resulting in 114 final participants with untreated OUD and HIV, with 62% positive for fentanyl, 60% positive for cocaine, and 47% positive for other opioids at the baseline. The intervention compared treatment as usual (TAU) of methadone or buprenorphine with extended-release naltrexone (XR-NTX) on group differences in viral suppression at 24 weeks and past 30-day use of opioids at 24 weeks. The study reported that at 24 weeks the outcome of viral suppression was similar for TAU and XR-NTX, and that fewer XR-NTX participants initiated medication than TAU participants. The outcome of previous 30-day use of opioids was similar for TAU as compared to XR-NTX. Of those participants who did initiate medication, those administered XR-NTX experienced less days of opioid use when compared with TAU in the prior 30 days. The researchers reported that the study evidence was not conclusive but did support that XR-NTX is not inferior to TAU for HIV viral suppression, and that study participants who started XR-NTX used less opioids at 24 weeks than participants who were administered TAU.
AHRQ-funded; HS026370.
Citation: Korthuis PT, Cook RR, Lum PJ .
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Addiction 2022 Jul;117(7):1961-71. doi: 10.1111/add.15836..
Keywords: Human Immunodeficiency Virus (HIV), Opioids, Substance Abuse, Behavioral Health, Medication, Treatments, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice
Griffith DC, Farmer C, Gebo KA
Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research Network.
Researchers studied the impact of single-tablet regiments (STRs) versus multi-tablet regimens (MTRs) in the treatment of HIV with youth with HIV (YHIV) in the HIV Research Network between the ages of 13 and 24. The use of STRs was associated with greater compliance in their antiretroviral regiments and better outcomes over an 8-year period (2006-2014) at 18 US HIV clinical sites.
AHRQ-funded; 290201100007C.
Citation: Griffith DC, Farmer C, Gebo KA .
Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research Network.
HIV Med 2019 Feb;20(2):169-74. doi: 10.1111/hiv.12695..
Keywords: Children/Adolescents, Human Immunodeficiency Virus (HIV), Medication, Outcomes, Patient Adherence/Compliance, Patient-Centered Outcomes Research, Young Adults
Agwu AL, Fleishman JA, Mahiane G
AHRQ Author: Fleishman JA
Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: results from the HIVRN Cohort.
This study compared combination antiretroviral therapy (cART). outcomes over time following cART initiation between ART-naive non-perinatally HIV-infected (nPHIV) youth (13-24 years-old) and adults (>/=25-44 years-old). It found that despite having residual thymic tissue, youth attain similar, not superior, CD4 (T-lymphocyte cells) gains as adults.
AHRQ-authored.
Citation: Agwu AL, Fleishman JA, Mahiane G .
Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: results from the HIVRN Cohort.
PLoS One 2017 Feb 9;12(2):e0171125. doi: 10.1371/journal.pone.0171125.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Outcomes, Medication
McManus KA, Rhodes A, Bailey S
Affordable Care Act qualified health plan coverage: association with improved HIV viral suppression for AIDS drug assistance program clients in a Medicaid nonexpansion state.
The objective of this study was to characterize the demographic and healthcare delivery factors associated with Virginia AIDS Drug Assistance Programs (ADAPs) clients' qualified health plan (QHP) enrollment and to assess the relationship between qualified health coverage and human immunodeficiency virus (HIV) viral suppression. It concluded that QHP coverage was associated with viral suppression, an essential outcome for individuals and for public health.
AHRQ-funded; HS024196.
Citation: McManus KA, Rhodes A, Bailey S .
Affordable Care Act qualified health plan coverage: association with improved HIV viral suppression for AIDS drug assistance program clients in a Medicaid nonexpansion state.
Clin Infect Dis 2016 Aug;63(3):396-403. doi: 10.1093/cid/ciw277.
.
.
Keywords: Health Insurance, Human Immunodeficiency Virus (HIV), Medicaid, Medication, Outcomes